Golden
Arpeggio Biosciences

Arpeggio Biosciences

A a biotechnology company developing a drug-screening platform for the acceleration of drug discovery by combining custom laboratory assay and proprietary machine learning algorithms.

All edits by  Dawson Sewell 

Edits on 13 Aug 2019
Dawson Sewell
Dawson Sewell edited on 13 Aug 2019 12:59 pm
Edits made to:
Infobox (+5 properties)
Description (+1/-23 characters)
Article (+1104 characters)
Topic thumbnail

Arpeggio Biosciences

Arpeggio Biosciences isA a biotechnology company developing a drug-screening platform for the acceleration of drug discovery by combining custom laboratory assay and proprietary machine learning algorithms.

Article

Arpeggio Biosciences is a biotechnology company headquartered in Boulder, Colorado that was founded in 2017 by Robin Dowell and Joey Azofeifa. Arpeggio Biosciences headquarters is located in the BioFrontiers Institute in the University of Boulder Colorado. The company is developing a drug-screening platform for the acceleration of drug discovery by combining custom laboratory assay and proprietary machine learning algorithms.

Drug screening

The companies drug screening platform is can be used by scientists performing research related to dug discovery and the mechanisms of actions underlying the effectiveness of drugs. The drug screening platform provides time series profiling of drug compounds using RNA-profiling technology to gain insight into how thousands of genes are interacting within the human body. The company than uses machine learning algorithms to analyze the time series profile to discover causal signalling networks which can give researchers insight into the underlying mechanisms of action for their drugs, and help them predict about how a certain drug will affect a patient. 

Infobox

Date incorporated
2017

No more activity to show.